Videos and Podcasts
Pharmaxis R&D Showcase Webinars - Recordings
Pharmaxis Ltd recently hosted R&D Showcase Webinars for each of the Company’s two lead drug discoveries. Presentations by globally renowned clinicians and scientists involved in the Company’s clinical programs were followed by Q&A sessions spearheaded by selected panels of biotech analysts and fund managers. The webinars were moderated by Michael Woods.
Showcase Webinar #1: Pharmaxis Drug PXS-5505 Targeting Several Cancers.
Presentation |
Speaker |
Link to recording |
Welcome and Introduction to Pharmaxis research and clinical development program |
Michael Woods Dr Wolfgang Jarolimek Gary Phillips |
|
The myelofibrosis landscape and MF-101 |
Dr Gabriela Hobbs (Massachusetts General Hospital) |
|
Hepatocellular cancer and Rochester University investigator led study |
Dr Paul Burchard (Rochester NY) |
|
Pancreatic Cancer |
Dr Tom Cox |
|
Pharmaxis Q&A |
Gary Phillips |
Panel members: Hashan Da Silva (Karst Peak), Bianca Ogden (Platinum), Dennis Hulme (Taylor Collison) and Derek Jellinek (Morgans)
A pdf of the presentations is available here.
Showcase Webinar #2: Pharmaxis Drug PXS-6302 Designed to Target Skin Scarring.
Presentation |
Speaker |
Link to recording |
Welcome and Introduction to Pharmaxis – a global leader in lysyl oxidase chemistry and biology |
Gary Phillips |
|
The science of scarring and potential for LOX inhibition |
Dr Mark Fear (UWA) |
|
Clinical applications for LOX inhibition |
Professor Fiona Wood (UWA) |
|
Q&A with panel |
Panel members: Scott Power (Morgan), David Nayagam (Evans and Partners) and Chris Kallos (MST Access)
A pdf of the presentations is available here.
Pharmaxis teams with renowned surgeon Fiona Wood for scar tissue trial
Pharmaxis CEO Gary Phillips speaks to Proactive about the company's phase 1c scar tissue trial, led by world-renowned surgeon Fiona Wood AM. The three-month, placebo-controlled clinical study has already dosed its first patient with Pharmaxis' novel, topical drug treatment for scarring. Fifty patients with established scars will participate in the trial as PXS looks to develop a treatment in a market valued at US$3.5 billion a year.
Watch the interview here
Investor briefing - 31 January 2022
Pharmaxis Ltd (ASX: PXS) released its Quarterly Shareholder Update on the morning of 31 January 2022.
Investors and analysts joined the Company for a virtual investor briefing by chief executive officer Mr Gary Phillips.
The event consisted of a short presentation of the Company’s progress over the past quarter and future plans followed by a Q&A session from attendees. You can watch a recording of the presentation below.
Watch recording here.